Create Free Account

By creating account you will get access to hot stocks & personalised emails

Progyny Inc

Healthcare US PGNY

14.09USD
-0.41(2.83%)

Last update at 2024-12-19T18:52:00Z

Day Range

13.8614.49
LowHigh

52 Week Range

23.9044.95
LowHigh

Fundamentals

  • Previous Close 14.50
  • Market Cap2539.54M
  • Volume610015
  • P/E Ratio44.45
  • Dividend Yield-%
  • EBITDA68.15M
  • Revenue TTM1108.28M
  • Revenue Per Share TTM11.58
  • Gross Profit TTM 167.32M
  • Diluted EPS TTM0.60

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 24.44M 32.44M 8.68M -8.55700M -6.89300M
Minority interest - - - - -
Net income 30.36M 65.77M 46.46M -8.56900M 0.66M
Selling general administrative 98.33M 59.62M 46.70M 23.93M 15.60M
Selling and marketing expenses 45.66M 20.18M 15.01M 11.90M 7.29M
Gross profit 167.32M 112.14M 70.06M 45.51M 19.43M
Reconciled depreciation 1.60M 1.30M 1.91M 2.13M 1.88M
Ebit 23.34M 32.34M 8.35M 27.85M -0.50800M
Ebitda 24.94M 33.64M 10.25M 29.99M 1.38M
Depreciation and amortization 1.60M 1.30M 1.91M 2.13M 1.88M
Non operating income net other 0.29M -0.36600M 0.21M - -
Operating income 23.34M 32.34M 8.35M 27.85M -3.45200M
Other operating expenses 763.57M 468.28M 336.51M 220.01M 108.85M
Interest expense 0.81M 0.46M 0.12M -0.49700M 0.00000M
Tax provision -5.91700M -33.33400M -37.78000M 0.01M -1.77700M
Interest income 0.81M - - 0.06M 0.50M
Net interest income 0.81M 0.46M 0.12M -0.05800M -0.49700M
Extraordinary items - - - - 5.78M
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.91700M -33.33400M -37.78000M 0.01M -1.77700M
Total revenue 786.91M 500.62M 344.86M 229.68M 105.40M
Total operating expenses 143.98M 79.80M 61.71M 35.83M 22.89M
Cost of revenue 619.59M 388.49M 274.80M 184.18M 85.97M
Total other income expense net 1.10M 0.10M 0.33M -36.41000M -2.94400M
Discontinued operations - - - - 5.78M
Net income from continuing ops 30.36M 65.77M 46.46M -8.56900M -5.11600M
Net income applicable to common shares 30.36M 65.77M 46.46M -8.56900M 0.24M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 756.62M 542.99M 358.06M 253.93M 150.43M
Intangible assets - 0.10M 0.60M 1.21M 2.38M
Earning assets - - - - -
Other current assets 27.45M 4.49M 4.56M 5.26M 5.00M
Total liab 203.19M 166.02M 106.24M 86.98M 36.16M
Total stockholder equity 553.43M 376.97M 251.82M 166.95M 114.27M
Deferred long term liab - - - - -
Other current liab 1.18M 49.02M 2.17M 34.27M 16.77M
Common stock 0.00900M 0.00900M 0.00900M 0.00900M 0.00800M
Capital stock 0.00900M 0.00900M 0.00900M 0.00900M 0.00800M
Retained earnings 89.97M 27.93M -2.42400M -68.19300M -113.48300M
Other liab - - - 0.88M -
Good will 11.88M 11.88M 11.88M 11.88M 11.88M
Other assets - 81.88M 74.22M 8.22M 0.65M
Cash 97.30M 120.08M 91.41M 70.31M 80.38M
Cash and equivalents - - - - -
Total current liabilities 185.95M 159.54M 98.82M 77.79M 36.16M
Current deferred revenue 57.19M - 34.02M - -
Net debt -77.90600M -112.36500M -83.99400M -61.98700M -80.38200M
Short term debt 2.15M 1.23M 1.23M 0.25M -
Short long term debt - - - - -
Short long term debt total 19.39M 7.71M 7.42M 8.32M -
Other stockholder equity 460.63M 348.52M 254.33M 235.13M 227.75M
Property plant equipment - 8.37M 12.83M 3.40M 3.08M
Total current assets 640.41M 433.86M 258.54M 190.22M 132.44M
Long term investments - - - - -
Net tangible assets - 364.99M 239.34M 153.85M 100.02M
Short term investments 273.79M 69.22M 28.00M 38.99M -
Net receivables 241.87M 240.07M 134.56M 75.66M 47.06M
Long term debt - - - - -
Inventory 0.00000M - - - -
Accounts payable 125.43M 109.29M 61.40M 43.51M 19.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.82M 0.50M -0.09300M 0.00100M -150.43400M
Additional paid in capital - - - - -
Common stock total equity - 0.00900M 0.00900M 0.00900M 0.00800M
Preferred stock total equity - - - - -
Retained earnings total equity - 27.93M -2.42400M -68.19300M -
Treasury stock - - - - -1.00900M
Accumulated amortization - - - - -
Non currrent assets other 3.40M 3.99M 2.94M 0.57M 0.65M
Deferred long term asset charges - - - - -
Non current assets total 116.21M 109.13M 99.53M 63.70M 17.99M
Capital lease obligations 19.39M 6.48M 8.65M 8.32M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -43.86600M 10.89M -38.99400M -2.75600M 1.90M
Change to liabilities 60.84M 17.84M 42.41M 3.50M 10.45M
Total cashflows from investing activities -43.86600M 8.77M -40.03100M -2.75600M 1.90M
Net borrowings - - - -0.25300M -5.09800M
Total cash from financing activities -7.86400M -13.69500M -6.24900M 84.55M -8.73800M
Change to operating activities 12.12M -0.42100M 17.68M 1.89M 2.68M
Net income 30.36M 65.77M 46.46M -8.56900M 0.66M
Change in cash 28.66M 21.11M -10.07700M 80.25M -4.56400M
Begin period cash flow 91.41M 70.31M 80.38M 0.13M 4.69M
End period cash flow 120.08M 91.41M 70.31M 80.38M 0.13M
Total cash from operating activities 80.39M 26.04M 36.20M -1.53400M 2.27M
Issuance of capital stock - 0.00000M 0.00000M 78.39M 0.00000M
Depreciation 1.60M 1.30M 1.91M 2.13M 1.88M
Other cashflows from investing activities - - - 0.20M 2.48M
Dividends paid - - - - -
Change to inventory - 2.86M 17.07M 2.27M 2.58M
Change to account receivables -119.30400M -68.67600M -35.33600M -25.34200M -12.77600M
Sale purchase of stock 4.22M 4.27M 2.68M -0.18500M -3.70500M
Other cashflows from financing activities -10.93700M -13.69500M -6.24900M 188.62M 64.49M
Change to netincome 107.93M 10.22M -19.51300M 24.86M -0.70100M
Capital expenditures 3.24M 2.13M 1.04M 2.96M 0.58M
Change receivables -119.30400M -68.67600M -35.33600M - -
Cash flows other operating -1.02300M -2.60500M 0.28M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 28.66M 21.11M -10.07700M - -
Change in working capital -59.49100M -51.25700M 7.35M -19.95400M 0.35M
Stock based compensation 100.75M 33.71M 12.82M 5.06M 3.00M
Other non cash items 13.79M 9.82M 5.64M 19.78M -1.84600M
Free cash flow 77.15M 23.91M 35.17M -4.49000M 1.69M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PGNY
Progyny Inc		 -0.41 2.83% 14.09 44.45 48.08 3.03 5.96 2.71 45.71
GEHC
GE HealthCare Technologies Inc.		 0.62 0.80% 77.71 22.91 20.12 2.01 5.52 2.39 13.30
VEEV
Veeva Systems Inc Class A		 -2.02 0.91% 219.52 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc		 - -% 9.73 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc		 -0.13 2.97% 4.25 31.84 26.25 0.05 4.60 0.04 0.12

Reports Covered

Stock Research & News

View All

Profile

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Progyny Inc

1359 Broadway, New York, NY, United States, 10018

Key Executives

Name Title Year Born
Mr. David J. Schlanger Exec. Chairman 1959
Mr. Peter Anevski CEO & Director 1967
Mr. Mark S. Livingston Chief Financial Officer 1966
Mr. Michael Sturmer Pres 1977
Mr. James Hart VP of Investor Relations NA
Ms. Risa Fisher Exec. VP & Chief Marketing Officer NA
Ms. Cassandra Pratt Sr. VP of People NA
Ms. Julie Stadlbauer Exec. VP of Strategic Sales & Partnerships NA
Ms. Arielle Bogorad Sr. VP of Employer Market Strategy NA
Allison Swartz Exec. VP & GC NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.